查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1397033

藥物栓劑市場：按類型、按基地、按配銷通路、按最終用戶、按處方類型：2023-2032 年全球機會分析和行業預測

Pharmaceutical Suppositories Market By Type, By Base, By Distribution Channel, By End User, By Prescription Type : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 377 Pages | 商品交期: 2-3個工作天內

價格

2022年，藥用栓劑市場價值為160,646萬美元，預計到2032年將達到280,205萬美元，2023年至2032年的年複合成長率為5.7%。

栓劑是專門設計用於插入口腔以外的體腔內的固態劑型。可放入直腸、陰道、尿道等處。這些藥物被設計為溶解或溶解在腔液中並在插入後釋放藥物。依插入部位的不同，栓劑分為直腸栓劑、陰道栓劑和尿道栓劑。栓劑在現場行動上具有效用。可以消除使藥物免於代謝的首過效應。對於苦味或令人不快的藥物，可以使用栓劑作為藥物傳輸選擇。在小兒科中，栓劑常用於治療類似便秘的病症。然而，它可能會引起使用部位的黏膜刺激，這可能會限制其使用。

需要使用栓劑的慢性疾病盛行率的增加是藥物栓劑市場的關鍵促進因素。發炎性腸道疾病、痔瘡和某些癌症等慢性疾病通常受益於局部給藥，減少全身副作用。由於生活方式的改變和人口高齡化等多種因素，這些疾病變得更加常見，對栓劑治療的需求將會增加。例如，根據國家醫學圖書館發表的一篇論文，加拿大有 320,000 人患有發炎性腸道疾病疾病(IBD)，到 2035 年，1.1% 的人口，即 470,000 名加拿大人將患有 IBD。盛行率是預計每年增加2.44%，其中包括預計患病人數的增加。

這一趨勢為製藥公司帶來了巨大的成長機會，導致新配方的開拓和塞劑市場的擴大，以滿足慢性病患者的醫療保健需求。

然而，由於穩定性和溶解度問題，並非所有藥物都可以透過栓劑有效輸送，這限制了藥物相容性並阻礙了市場成長。此外，製造的複雜性以及對專業設備和製程的需求增加了生產成本並限制了製造商的數量，從而限制了市場准入和承受能力。

藥用栓劑市場分為類型、基地、配銷通路、最終用戶、處方類型和地區。依類型分類，市場分為直腸栓劑、陰道栓劑和尿道栓劑。基質分為脂肪基質、水溶性基質和乳化基質。水溶性基質又分為甘油明膠基質、皂甘油栓劑和聚乙二醇基質。乳化基質又分為witepsol、masaesterium、masapol。

依配銷通路，市場分為醫院藥房、零售藥房和線上銷售。依最終使用者分為醫院/診所、居家醫療和護理機構。依處方類型，栓劑分為OTC栓劑和處方栓劑。按地區分類，對北美、歐洲、亞太地區和拉丁美洲地區市場進行了分析。藥物栓劑市場的一些主要企業包括拜耳公司、Bliss Gvs Pharma Ltd、Viatris Inc、Cadila Healthcare Ltd、Church &Dwight Co., Inc、Glenmark Pharmaceuticals Limited、Intas Pharmaceuticals Ltd、Novartis AG 和 Pfizer Inc.。賽諾菲公司等

塞劑提供了一種極佳的藥物傳遞替代方案，對於失去知覺的患者或需要直接作用時非常有用。

老年人口增加、全球胃腸道疾病數量增加、子宮內疾病和各種慢性病數量增加、醫院和診所數量增加等因素預計將推動藥用栓劑市場的成長。此外，直腸栓劑使用量的增加和技術進步進一步推動了市場成長。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 需要使用塞劑的急性和慢性疾病盛行率上升
      • 老年人口增加
      • 加強對栓劑使用的認知與教育配合措施
    • 抑制因素
      • 製造複雜性
      • 藥物相容性限制
    • 機會
      • 栓劑的技術進步

第4章藥物栓劑市場：依類型

  • 概述
  • 直腸栓劑
  • 陰道栓劑
  • 尿道栓劑

第5章藥物栓劑市場：依基質

  • 概述
  • 脂肪鹼
  • 水混溶性鹼
    • 以水溶性基質類型分類的藥物栓劑市場
  • 乳化基
    • 以乳化基質類型分類的藥物栓劑市場

第6章藥物栓劑市場：依配銷通路

  • 概述
  • 醫院藥房
  • 零售藥房
  • 線上銷售

第7章藥物栓劑市場：依最終用戶分類

  • 概述
  • 醫院/診所
  • 居家醫療
  • 療養院

第8章藥物栓劑市場：依處方類型

  • 概述
  • 非處方藥物
  • 處方栓劑

第9章藥物栓劑市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第10章競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第11章 公司簡介

  • Bayer AG
  • Bliss GVS Pharma Ltd
  • Viatris Inc.
  • Church & Dwight Co. Inc.
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Product Code: A12350

The Pharmaceutical Suppositories Market was valued for $1,606.46 million in 2022 and is estimated to reach $2,802.05 million by 2032, exhibiting a CAGR of 5.7% from 2023 to 2032.

Suppositories are solid dosage forms of medication that are precisely designed for insertion into bodily cavities other than the mouth. They can be placed in the rectum, vaginal canal, or urethra. These items are designed to melt or dissolve in the cavity fluids after insertion, allowing the drug to be released. On the basis of the site of insertion, suppositories are divided into rectal suppository, vaginal suppository, and urethral suppository. Suppositories have usefulness in on-site action. It omits the first-pass effect which save drug from metabolism. In case of bitter and obnoxious drugs, suppositories are used as drug delivering option. In pediatrics, suppositories are often used to treat symptoms similar to constipation. However, there is a possibility of mucosal irritation at the site of use which may limit its usage.

The increase in prevalence of chronic diseases that necessitate the use of suppositories is a significant driver for the pharmaceutical suppositories market. Chronic conditions such as inflammatory bowel disease, hemorrhoids, and certain cancers often benefit from localized drug delivery, reducing systemic side effects. The demand for suppository-based treatments rises as these conditions become more common due to various factors such as lifestyle changes and aging populations. For instance, according to the article published in National Library of Medicine, stated that 320,000 people in Canada have been living with Inflammatory bowel disease (IBD), and the prevalence is forecasted to rise by 2.44% per year such 1.1% of the population, 470,000 Canadians, are anticipated to live with IBD by 2035.

This trend offers substantial growth opportunities for pharmaceutical companies, leading to the development of new formulations and expanding the market for suppository-based medications to meet the healthcare needs of individuals with chronic diseases.

However, limited drug compatibility hinders market growth as not all medications are effectively delivered through suppositories due to stability and solubility issues. In addition, manufacturing complexities, requiring specialized equipment and processes, increase production costs and restrict the number of manufacturers, limiting market accessibility and affordability.

The pharmaceutical suppositories market is segmented into type, base, distribution channel, end user, prescription type and region. On the basis of type, the market is divided into rectal suppositories, vaginal suppositories and urethral suppositories. On the basis of base, it is classified into fatty base, water miscible bases, and emulsifying bases. The water miscible bases are further segmented into glycero gelatin base, soap glycerin suppositories, and polyethylene glycol bases. The emulsifying bases are further segmented into witepsol, massa esterium, and massuppol.

On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies and online sales. On the basis of end user, it is classified into hospitals & clinics, home care and nursing home. On the basis of prescription type, it is bifurcated into OTC and prescribed suppositories. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The major players that operate in the pharmaceutical suppositories market include Bayer AG, Bliss Gvs Pharma Ltd, Viatris Inc, Cadila Healthcare Ltd, Church & Dwight Co., Inc., Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., and Sanofi S.A.

suppositories provide great alternative of drug delivery and can be useful in case of unconscious patients or where direct on-site action is desired.

The factors such as increased geriatric population, rise in number of gastro-intestinal diseases across the globe, rise in intra uterine diseases and various chronic diseases and rise in number of hospitals & clinics are expected to drive the growth of the pharmaceutical suppositories market. Moreover, the increase in use of rectal suppositories and technological advancements further boost the growth of the market.

In addition, North America is expected to witness the highest growth, in terms of revenue, owing to ongoing technological advancements, a well-established and advanced healthcare infrastructure, and adoption of suppositories for treatment by patients and healthcare providers. However, Asia-Pacific is anticipated to witness notable growth, owing to a rise in geriatric population and an increase in initiative to expand the healthcare facilities in the region, thus driving the growth of the market during the forecast period.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pharmaceutical suppositories market analysis from 2022 to 2032 to identify the prevailing pharmaceutical suppositories market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the pharmaceutical suppositories market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global pharmaceutical suppositories market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles

Key Market Segments

By Type

  • Rectal Suppositories
  • Vaginal Suppositories
  • Urethral Suppositories

By Base

  • Fatty Bases
  • Water Miscible Base
    • Type
    • Glycero Gelatin Base
    • Soap Glycerin Suppositories
    • Polyethylene Glycol Bases
  • Emulsifying Bases
    • Type
    • Witepsol
    • Massa Esterium
    • Massuppol

By End User

  • Hospitals and Clinics
  • Home Care
  • Nursing Home

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

By Prescription Type

  • OTC
  • Prescribed Suppositories

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bayer AG
    • Church & Dwight Co. Inc.
    • Cadila Healthcare Ltd
    • Pfizer Inc.
    • Intas Pharmaceuticals Ltd.
    • Viatris Inc.
    • Novartis AG
    • Sanofi S.A.
    • Bliss GVS Pharma Ltd
    • Glenmark Pharmaceuticals Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of acute & chronic disorders which require the use of suppository
      • 3.4.1.2. Increase in the geriatric population
      • 3.4.1.3. Increase in initiatives for awareness and education for use of suppositories
    • 3.4.2. Restraints
      • 3.4.2.1. Manufacturing complexities
      • 3.4.2.2. Limited drug compatibility
    • 3.4.3. Opportunities
      • 3.4.3.1. Technological advancements in suppositories

CHAPTER 4: PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Rectal Suppositories
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Vaginal Suppositories
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Urethral Suppositories
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Fatty Bases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Water Miscible Base
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
    • 5.3.4. Water Miscible Base Pharmaceutical Suppositories Market by Type
  • 5.4. Emulsifying Bases
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
    • 5.4.4. Emulsifying Bases Pharmaceutical Suppositories Market by Type

CHAPTER 6: PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Sales
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospitals and Clinics
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Home Care
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Nursing Home
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE

  • 8.1. Overview
    • 8.1.1. Market size and forecast
  • 8.2. OTC
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by region
    • 8.2.3. Market share analysis by country
  • 8.3. Prescribed Suppositories
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by region
    • 8.3.3. Market share analysis by country

CHAPTER 9: PHARMACEUTICAL SUPPOSITORIES MARKET, BY REGION

  • 9.1. Overview
    • 9.1.1. Market size and forecast By Region
  • 9.2. North America
    • 9.2.1. Key market trends, growth factors and opportunities
    • 9.2.2. Market size and forecast, by Type
    • 9.2.3. Market size and forecast, by Base
    • 9.2.4. Market size and forecast, by Distribution Channel
    • 9.2.5. Market size and forecast, by End User
    • 9.2.6. Market size and forecast, by Prescription Type
    • 9.2.7. Market size and forecast, by country
      • 9.2.7.1. U.S.
      • 9.2.7.1.1. Market size and forecast, by Type
      • 9.2.7.1.2. Market size and forecast, by Base
      • 9.2.7.1.3. Market size and forecast, by Distribution Channel
      • 9.2.7.1.4. Market size and forecast, by End User
      • 9.2.7.1.5. Market size and forecast, by Prescription Type
      • 9.2.7.2. Canada
      • 9.2.7.2.1. Market size and forecast, by Type
      • 9.2.7.2.2. Market size and forecast, by Base
      • 9.2.7.2.3. Market size and forecast, by Distribution Channel
      • 9.2.7.2.4. Market size and forecast, by End User
      • 9.2.7.2.5. Market size and forecast, by Prescription Type
      • 9.2.7.3. Mexico
      • 9.2.7.3.1. Market size and forecast, by Type
      • 9.2.7.3.2. Market size and forecast, by Base
      • 9.2.7.3.3. Market size and forecast, by Distribution Channel
      • 9.2.7.3.4. Market size and forecast, by End User
      • 9.2.7.3.5. Market size and forecast, by Prescription Type
  • 9.3. Europe
    • 9.3.1. Key market trends, growth factors and opportunities
    • 9.3.2. Market size and forecast, by Type
    • 9.3.3. Market size and forecast, by Base
    • 9.3.4. Market size and forecast, by Distribution Channel
    • 9.3.5. Market size and forecast, by End User
    • 9.3.6. Market size and forecast, by Prescription Type
    • 9.3.7. Market size and forecast, by country
      • 9.3.7.1. Germany
      • 9.3.7.1.1. Market size and forecast, by Type
      • 9.3.7.1.2. Market size and forecast, by Base
      • 9.3.7.1.3. Market size and forecast, by Distribution Channel
      • 9.3.7.1.4. Market size and forecast, by End User
      • 9.3.7.1.5. Market size and forecast, by Prescription Type
      • 9.3.7.2. France
      • 9.3.7.2.1. Market size and forecast, by Type
      • 9.3.7.2.2. Market size and forecast, by Base
      • 9.3.7.2.3. Market size and forecast, by Distribution Channel
      • 9.3.7.2.4. Market size and forecast, by End User
      • 9.3.7.2.5. Market size and forecast, by Prescription Type
      • 9.3.7.3. UK
      • 9.3.7.3.1. Market size and forecast, by Type
      • 9.3.7.3.2. Market size and forecast, by Base
      • 9.3.7.3.3. Market size and forecast, by Distribution Channel
      • 9.3.7.3.4. Market size and forecast, by End User
      • 9.3.7.3.5. Market size and forecast, by Prescription Type
      • 9.3.7.4. Italy
      • 9.3.7.4.1. Market size and forecast, by Type
      • 9.3.7.4.2. Market size and forecast, by Base
      • 9.3.7.4.3. Market size and forecast, by Distribution Channel
      • 9.3.7.4.4. Market size and forecast, by End User
      • 9.3.7.4.5. Market size and forecast, by Prescription Type
      • 9.3.7.5. Spain
      • 9.3.7.5.1. Market size and forecast, by Type
      • 9.3.7.5.2. Market size and forecast, by Base
      • 9.3.7.5.3. Market size and forecast, by Distribution Channel
      • 9.3.7.5.4. Market size and forecast, by End User
      • 9.3.7.5.5. Market size and forecast, by Prescription Type
      • 9.3.7.6. Rest of Europe
      • 9.3.7.6.1. Market size and forecast, by Type
      • 9.3.7.6.2. Market size and forecast, by Base
      • 9.3.7.6.3. Market size and forecast, by Distribution Channel
      • 9.3.7.6.4. Market size and forecast, by End User
      • 9.3.7.6.5. Market size and forecast, by Prescription Type
  • 9.4. Asia-Pacific
    • 9.4.1. Key market trends, growth factors and opportunities
    • 9.4.2. Market size and forecast, by Type
    • 9.4.3. Market size and forecast, by Base
    • 9.4.4. Market size and forecast, by Distribution Channel
    • 9.4.5. Market size and forecast, by End User
    • 9.4.6. Market size and forecast, by Prescription Type
    • 9.4.7. Market size and forecast, by country
      • 9.4.7.1. Japan
      • 9.4.7.1.1. Market size and forecast, by Type
      • 9.4.7.1.2. Market size and forecast, by Base
      • 9.4.7.1.3. Market size and forecast, by Distribution Channel
      • 9.4.7.1.4. Market size and forecast, by End User
      • 9.4.7.1.5. Market size and forecast, by Prescription Type
      • 9.4.7.2. China
      • 9.4.7.2.1. Market size and forecast, by Type
      • 9.4.7.2.2. Market size and forecast, by Base
      • 9.4.7.2.3. Market size and forecast, by Distribution Channel
      • 9.4.7.2.4. Market size and forecast, by End User
      • 9.4.7.2.5. Market size and forecast, by Prescription Type
      • 9.4.7.3. Australia
      • 9.4.7.3.1. Market size and forecast, by Type
      • 9.4.7.3.2. Market size and forecast, by Base
      • 9.4.7.3.3. Market size and forecast, by Distribution Channel
      • 9.4.7.3.4. Market size and forecast, by End User
      • 9.4.7.3.5. Market size and forecast, by Prescription Type
      • 9.4.7.4. India
      • 9.4.7.4.1. Market size and forecast, by Type
      • 9.4.7.4.2. Market size and forecast, by Base
      • 9.4.7.4.3. Market size and forecast, by Distribution Channel
      • 9.4.7.4.4. Market size and forecast, by End User
      • 9.4.7.4.5. Market size and forecast, by Prescription Type
      • 9.4.7.5. South Korea
      • 9.4.7.5.1. Market size and forecast, by Type
      • 9.4.7.5.2. Market size and forecast, by Base
      • 9.4.7.5.3. Market size and forecast, by Distribution Channel
      • 9.4.7.5.4. Market size and forecast, by End User
      • 9.4.7.5.5. Market size and forecast, by Prescription Type
      • 9.4.7.6. Rest of Asia-Pacific
      • 9.4.7.6.1. Market size and forecast, by Type
      • 9.4.7.6.2. Market size and forecast, by Base
      • 9.4.7.6.3. Market size and forecast, by Distribution Channel
      • 9.4.7.6.4. Market size and forecast, by End User
      • 9.4.7.6.5. Market size and forecast, by Prescription Type
  • 9.5. LAMEA
    • 9.5.1. Key market trends, growth factors and opportunities
    • 9.5.2. Market size and forecast, by Type
    • 9.5.3. Market size and forecast, by Base
    • 9.5.4. Market size and forecast, by Distribution Channel
    • 9.5.5. Market size and forecast, by End User
    • 9.5.6. Market size and forecast, by Prescription Type
    • 9.5.7. Market size and forecast, by country
      • 9.5.7.1. Brazil
      • 9.5.7.1.1. Market size and forecast, by Type
      • 9.5.7.1.2. Market size and forecast, by Base
      • 9.5.7.1.3. Market size and forecast, by Distribution Channel
      • 9.5.7.1.4. Market size and forecast, by End User
      • 9.5.7.1.5. Market size and forecast, by Prescription Type
      • 9.5.7.2. Saudi Arabia
      • 9.5.7.2.1. Market size and forecast, by Type
      • 9.5.7.2.2. Market size and forecast, by Base
      • 9.5.7.2.3. Market size and forecast, by Distribution Channel
      • 9.5.7.2.4. Market size and forecast, by End User
      • 9.5.7.2.5. Market size and forecast, by Prescription Type
      • 9.5.7.3. South Africa
      • 9.5.7.3.1. Market size and forecast, by Type
      • 9.5.7.3.2. Market size and forecast, by Base
      • 9.5.7.3.3. Market size and forecast, by Distribution Channel
      • 9.5.7.3.4. Market size and forecast, by End User
      • 9.5.7.3.5. Market size and forecast, by Prescription Type
      • 9.5.7.4. Rest of LAMEA
      • 9.5.7.4.1. Market size and forecast, by Type
      • 9.5.7.4.2. Market size and forecast, by Base
      • 9.5.7.4.3. Market size and forecast, by Distribution Channel
      • 9.5.7.4.4. Market size and forecast, by End User
      • 9.5.7.4.5. Market size and forecast, by Prescription Type

CHAPTER 10: COMPETITIVE LANDSCAPE

  • 10.1. Introduction
  • 10.2. Top winning strategies
  • 10.3. Product mapping of top 10 player
  • 10.4. Competitive dashboard
  • 10.5. Competitive heatmap
  • 10.6. Top player positioning, 2022

CHAPTER 11: COMPANY PROFILES

  • 11.1. Bayer AG
    • 11.1.1. Company overview
    • 11.1.2. Key executives
    • 11.1.3. Company snapshot
    • 11.1.4. Operating business segments
    • 11.1.5. Product portfolio
    • 11.1.6. Business performance
  • 11.2. Bliss GVS Pharma Ltd
    • 11.2.1. Company overview
    • 11.2.2. Key executives
    • 11.2.3. Company snapshot
    • 11.2.4. Operating business segments
    • 11.2.5. Product portfolio
    • 11.2.6. Business performance
  • 11.3. Viatris Inc.
    • 11.3.1. Company overview
    • 11.3.2. Key executives
    • 11.3.3. Company snapshot
    • 11.3.4. Operating business segments
    • 11.3.5. Product portfolio
    • 11.3.6. Business performance
  • 11.4. Church & Dwight Co. Inc.
    • 11.4.1. Company overview
    • 11.4.2. Key executives
    • 11.4.3. Company snapshot
    • 11.4.4. Operating business segments
    • 11.4.5. Product portfolio
    • 11.4.6. Business performance
  • 11.5. Glenmark Pharmaceuticals Limited
    • 11.5.1. Company overview
    • 11.5.2. Key executives
    • 11.5.3. Company snapshot
    • 11.5.4. Operating business segments
    • 11.5.5. Product portfolio
    • 11.5.6. Business performance
  • 11.6. Intas Pharmaceuticals Ltd.
    • 11.6.1. Company overview
    • 11.6.2. Key executives
    • 11.6.3. Company snapshot
    • 11.6.4. Operating business segments
    • 11.6.5. Product portfolio
  • 11.7. Cadila Healthcare Ltd
    • 11.7.1. Company overview
    • 11.7.2. Key executives
    • 11.7.3. Company snapshot
    • 11.7.4. Operating business segments
    • 11.7.5. Product portfolio
    • 11.7.6. Business performance
    • 11.7.7. Key strategic moves and developments
  • 11.8. Novartis AG
    • 11.8.1. Company overview
    • 11.8.2. Key executives
    • 11.8.3. Company snapshot
    • 11.8.4. Operating business segments
    • 11.8.5. Product portfolio
    • 11.8.6. Business performance
  • 11.9. Pfizer Inc.
    • 11.9.1. Company overview
    • 11.9.2. Key executives
    • 11.9.3. Company snapshot
    • 11.9.4. Operating business segments
    • 11.9.5. Product portfolio
    • 11.9.6. Business performance
  • 11.10. Sanofi S.A.
    • 11.10.1. Company overview
    • 11.10.2. Key executives
    • 11.10.3. Company snapshot
    • 11.10.4. Operating business segments
    • 11.10.5. Product portfolio
    • 11.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. PHARMACEUTICAL SUPPOSITORIES MARKET FOR RECTAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. PHARMACEUTICAL SUPPOSITORIES MARKET FOR VAGINAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. PHARMACEUTICAL SUPPOSITORIES MARKET FOR URETHRAL SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 06. PHARMACEUTICAL SUPPOSITORIES MARKET FOR FATTY BASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. PHARMACEUTICAL SUPPOSITORIES MARKET FOR WATER MISCIBLE BASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL WATER MISCIBLE BASE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 09. PHARMACEUTICAL SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL EMULSIFYING BASES PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 12. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. PHARMACEUTICAL SUPPOSITORIES MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. PHARMACEUTICAL SUPPOSITORIES MARKET FOR ONLINE SALES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOME CARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. PHARMACEUTICAL SUPPOSITORIES MARKET FOR NURSING HOME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 20. PHARMACEUTICAL SUPPOSITORIES MARKET FOR OTC, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. PHARMACEUTICAL SUPPOSITORIES MARKET FOR PRESCRIBED SUPPOSITORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. PHARMACEUTICAL SUPPOSITORIES MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 29. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 31. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 34. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 36. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 39. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 41. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 44. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 46. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 49. EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 50. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 52. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 55. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 57. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 60. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 62. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. UK PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 65. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 66. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 67. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 70. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 72. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 75. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 76. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 77. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 80. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 81. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 82. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 84. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 85. ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 86. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 88. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 90. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 91. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 92. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 93. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 96. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 97. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 98. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 100. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 101. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 102. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 103. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 104. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 105. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 106. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 107. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 109. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 111. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 112. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 113. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 114. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 116. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 117. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 118. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 119. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 120. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 121. LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 122. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 123. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 124. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 125. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 126. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 128. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 129. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 130. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 131. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 132. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 133. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 134. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 135. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 136. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 137. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 140. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 141. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
  • TABLE 142. BAYER AG: KEY EXECUTIVES
  • TABLE 143. BAYER AG: COMPANY SNAPSHOT
  • TABLE 144. BAYER AG: PRODUCT SEGMENTS
  • TABLE 145. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 146. BLISS GVS PHARMA LTD: KEY EXECUTIVES
  • TABLE 147. BLISS GVS PHARMA LTD: COMPANY SNAPSHOT
  • TABLE 148. BLISS GVS PHARMA LTD: PRODUCT SEGMENTS
  • TABLE 149. BLISS GVS PHARMA LTD: PRODUCT PORTFOLIO
  • TABLE 150. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 151. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 152. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 153. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 154. CHURCH & DWIGHT CO. INC.: KEY EXECUTIVES
  • TABLE 155. CHURCH & DWIGHT CO. INC.: COMPANY SNAPSHOT
  • TABLE 156. CHURCH & DWIGHT CO. INC.: PRODUCT SEGMENTS
  • TABLE 157. CHURCH & DWIGHT CO. INC.: PRODUCT PORTFOLIO
  • TABLE 158. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
  • TABLE 159. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 160. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
  • TABLE 161. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 162. INTAS PHARMACEUTICALS LTD.: KEY EXECUTIVES
  • TABLE 163. INTAS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 164. INTAS PHARMACEUTICALS LTD.: PRODUCT SEGMENTS
  • TABLE 165. INTAS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 166. CADILA HEALTHCARE LTD: KEY EXECUTIVES
  • TABLE 167. CADILA HEALTHCARE LTD: COMPANY SNAPSHOT
  • TABLE 168. CADILA HEALTHCARE LTD: PRODUCT SEGMENTS
  • TABLE 169. CADILA HEALTHCARE LTD: PRODUCT PORTFOLIO
  • TABLE 170. CADILA HEALTHCARE LTD: KEY STRATERGIES
  • TABLE 171. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 172. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 173. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 174. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 175. PFIZER INC.: KEY EXECUTIVES
  • TABLE 176. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 177. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 178. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 179. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 180. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 181. SANOFI S.A.: PRODUCT SEGMENTS
  • TABLE 182. SANOFI S.A.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PHARMACEUTICAL SUPPOSITORIES MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN PHARMACEUTICAL SUPPOSITORIES MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN PHARMACEUTICAL SUPPOSITORIES MARKET (2023-2032)
  • FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL PHARMACEUTICAL SUPPOSITORIES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. PHARMACEUTICAL SUPPOSITORIES MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR RECTAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR VAGINAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR URETHRAL SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. PHARMACEUTICAL SUPPOSITORIES MARKET, BY BASE, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR FATTY BASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR WATER MISCIBLE BASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR EMULSIFYING BASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. PHARMACEUTICAL SUPPOSITORIES MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR ONLINE SALES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. PHARMACEUTICAL SUPPOSITORIES MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR HOME CARE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR NURSING HOME, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 27. PHARMACEUTICAL SUPPOSITORIES MARKET, BY PRESCRIPTION TYPE, 2022 AND 2032(%)
  • FIGURE 28. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR OTC, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL SUPPOSITORIES MARKET FOR PRESCRIBED SUPPOSITORIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 30. PHARMACEUTICAL SUPPOSITORIES MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 31. U.S. PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CANADA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. MEXICO PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. GERMANY PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. FRANCE PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. UK PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. ITALY PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SPAIN PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF EUROPE PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. JAPAN PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. CHINA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. AUSTRALIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. INDIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH KOREA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. REST OF ASIA-PACIFIC PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. BRAZIL PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. SAUDI ARABIA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. SOUTH AFRICA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. REST OF LAMEA PHARMACEUTICAL SUPPOSITORIES MARKET, 2022-2032 ($MILLION)
  • FIGURE 50. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
  • FIGURE 51. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
  • FIGURE 52. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
  • FIGURE 53. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 54. COMPETITIVE DASHBOARD
  • FIGURE 55. COMPETITIVE HEATMAP: PHARMACEUTICAL SUPPOSITORIES MARKET
  • FIGURE 56. TOP PLAYER POSITIONING, 2022
  • FIGURE 57. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. BLISS GVS PHARMA LTD: NET REVENUE, 2021-2023 ($MILLION)
  • FIGURE 61. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. CHURCH & DWIGHT CO. INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. CHURCH & DWIGHT CO. INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. GLENMARK PHARMACEUTICALS LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 66. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. CADILA HEALTHCARE LTD: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. CADILA HEALTHCARE LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 74. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 75. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 76. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 77. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)